The historical rank and industry rank for Voyager Therapeutics's Gross Margin % or its related term are showing as below:
FRA:VT6's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91 * Ranked among companies with meaningful Gross Margin % only.
Voyager Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Voyager Therapeutics was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Voyager Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Voyager Therapeutics Gross Margin % Related Terms
Voyager Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Voyager Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VT6 vs KROS, CDXS, CAMP: Gross Margin % Comparison
For the Biotechnology subindustry, Voyager Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Voyager Therapeutics (FRA:VT6) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #999999 out of 736 companies in the Biotechnology industry.
Is Voyager Therapeutics' Gross Margin % too high?
Voyager Therapeutics' current Gross Margin % is 0.00%. Based on the distribution chart, Voyager Therapeutics ranks #999999 out of 736 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Voyager Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Gross Margin % compare to KROS and CDXS?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #999999 out of 736 companies for Gross Margin %. This places Voyager Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Voyager Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyager Therapeutics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.39, compared to a current price of €2.94 — trading 111.8% above its estimated fair value. The current Gross Margin % is 0.00%. Voyager Therapeutics' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €2.94 is trading 111.8% above its estimated GF Value™ of €1.39.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
Gross Margin %: 0.00%
GF Value™: €1.39 vs. price of €2.94 (111.8% above fair value)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
57GF Score
Get the complete analysis for FRA:VT6
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
